1. Home
  2. SDA vs BMEA Comparison

SDA vs BMEA Comparison

Compare SDA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SDA

SunCar Technology Group Inc.

HOLD

Current Price

$0.78

Market Cap

82.4M

Sector

Finance

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.33

Market Cap

95.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SDA
BMEA
Founded
2007
2017
Country
China
United States
Employees
544
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.4M
95.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SDA
BMEA
Price
$0.78
$1.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$4.75
$9.83
AVG Volume (30 Days)
277.1K
1.0M
Earning Date
04-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.19
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.01
N/A
Revenue Next Year
$15.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.47
$0.87
52 Week High
$2.93
$2.99

Technical Indicators

Market Signals
Indicator
SDA
BMEA
Relative Strength Index (RSI) 45.36 51.07
Support Level $0.72 $1.23
Resistance Level $0.97 $1.46
Average True Range (ATR) 0.07 0.09
MACD 0.00 -0.00
Stochastic Oscillator 27.84 40.32

Price Performance

Historical Comparison
SDA
BMEA

About SDA SunCar Technology Group Inc.

SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: